Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Company Overview

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.00 to $0.75
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 1,715 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELOX Stock Analysis - Frequently Asked Questions

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) issued its earnings results on Monday, April, 3rd. The company reported ($2.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.97) by $0.05.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eloxx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eloxx Pharmaceuticals investors own include Tesla (TSLA), ADMA Biologics (ADMA), Adverum Biotechnologies (ADVM), Assertio (ASRT), Fulcrum Therapeutics (FULC), Acasti Pharma (ACST) and Akebia Therapeutics (AKBA).

Company Calendar

• Last Earnings: 4/03/2023
• Today: 5/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELOX
• CIK: 1035354
• Web: www.eloxxpharma.com
• Phone: (781) 577-5300
• Fax: 908-864-4440
• Employees: 30
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,143,000
• Free Float: 2,508,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -1,536.70